I don't think that is in-factual. If the examiner granted the patents due to secondary conditions on the basis of APO-B reductions and Kurabayashi suggested that EPA reduced Apo-B, it is a reasonable assumption to assume the examiner overlooked it. <br /> <br /> Monday could be bad. Look up Hikma's ANDA 208339. The FDA granted approval 3 days after the ruling against J&J's Zytiga, despite a pending appeal waiting. Generics want to claim the 180 exclusivity so they all will rush file.